New drug aims to cool burning pain of rare genetic disease
NCT ID NCT07262268
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 15 times
Summary
This early-stage study tests whether BHV-7000 can reduce chronic pain in people with inherited erythromelalgia, a rare genetic condition causing severe burning pain. Only 5 adults with a specific gene mutation will take part, receiving both the drug and a placebo at different times to compare effects. The main goal is to see if daily pain scores improve while on the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL ERYTHROMELALGIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site-001
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.